Merck Animal Health announced it has received license approval for Circumvent CML vaccine in the U.S. from the Department of Agriculture (USDA).
Circumvent CML is the first-ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, three weeks of age or older.
“Merck Animal Health is excited to bring this important innovation to our customers as part of our commitment to offering comprehensive solutions for improved animal health outcomes,” said Jamie Lehman, D.V.M., swine technical services veterinarian of Merck Animal Health. “This vaccine nicely complements Circumvent PCV G2, PCV-M G2 and Porcilis Ileitis product portfolio, providing swine veterinarians and producers the additional option of vaccinating against disease caused by PCV2, Mycoplasma hyopneumoniae and Lawsonia intracellularis all in one bottle.”
Circumvent CML will be commercially available starting in early 2023. It will come in 50-ml, 250-ml, and eventually, 500-ml dose presentations.
